Forest Pharmaceuticals, Inc. (FPI) can help you see the pharmaceuticals amidst the trees. The company develops, manufactures, and distributes a variety of prescription and OTC pharmaceutical products, including both branded and generic versions. Its product line includes Aerobid (asthma), Celexa and Lexapro (depression), Cervidil (cervical ripening), Tiazac (hypertension), and Namenda (Alzheimer's disease). FPI's products are marketed to physicians, hospitals, pharmacies, and managed care organizations in the US and Puerto Rico. The company, which operates manufacturing and packaging facilities in Missouri and Ohio, is a subsidiary of Forest Laboratories.

Vetoquinol S.A. was founded in 1933 and is based in Lure, France. Vétoquinol S A engages in the research and development, manufacture, marketing, and sale of medicines and nutraceuticals for animal health. It offers Marbocyl, an antibiotic for various species; Tolfédine and Tolfine anti-inflammatories for minimizing animal pain; and Prilium, an oral daily administration formula for cardiovascular treatment. The company’s products are used for dogs, cats, cattle, and pigs. It sells its products in Europe, North America, Africa, the Middle East, and the Pacific Asia. Vétoquinol S A was formerly known as Laboratoires Biochimiques de l’Est and changed its name to Vetoquinol S.A. in 1962.

Minrad International, Inc. company, through its Minrad Inc. subsidiary, develops real-time image guidance products used in anesthesiology, orthopedics, neurosurgery, and interventional radiology. The company's technologies, including its SabreSource system, improve accuracy in surgical procedures and reduce radiation exposure. Minrad also makes handheld surgical instruments and generic inhalation anesthetics used in human and veterinary surgeries. In addition, the company is developing other anesthetic drugs that relieve patients' pain during surgery without the loss of consciousness. Minrad belongs to Indian pharma firm Piramal Healthcare.

Simcere Pharmaceutical Group was founded in 1995 and is headquartered in Nanjing, the People's Republic of China. Simcere Pharmaceutical Group is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market. The Company has introduced a generic anti-stroke medication under the brand name Bicun, a 5-FU sustained release implant under the brand name Sinofuan and an anti-cancer medication under the brand name Endu. It manufactures and sells 45 principal pharmaceutical products and is the distributor of three additional pharmaceuticals that are manufactured by independent third parties but marketed under its brand names. On May 5, 2008, it acquired 70% interest in Wuhu Zhong Ren Pharmaceutical Co., Ltd. (Wuhu Simcere Zhong Ren). On January 6, 2009, Simcere Pharmaceutical Group acquired the remaining 10% of interest of Shandong Simcere Medgenn Bio-Pharmaceutical Co., Ltd. (Shandong Simcere).

Pain Therapeutics, Inc. was founded in 1998 and is based in San Mateo, California. Pain Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of novel drugs. It has four drug candidates in clinical development programs, which include Remoxy, a novel controlled-release oral capsule form of oxycodone; PTI-202 and PTI-721, which are abuse-resistant forms of opioid drugs; and PTI-188 for the treatment of metastatic melanoma. The company is also developing a technology for the treatment of hemophilia in patients. Pain Therapeutics, Inc. has a strategic alliance with King Pharmaceuticals, Inc. for the development and commercialization of Remoxy, PTI-202, PTI-721, and other abuse-resistant opioid painkillers.

Elixir Pharmaceuticals concocts treatments targeting metabolic diseases and disorders. Dedicated to the discovery, development, and commercialization of treatments for such diseases as diabetes and obesity, the company has taken a dual approach to its work: licensing products from other pharmaceutical companies for development and pursuing proprietary products. Product candidates currently under development include Glinsuna and Metgluna as treatment for type 2 diabetes and a ghrelin antagonist as a treatment for a range of metabolic disorders (all in phase III testing). The company is also exploring the use of sirtuin modulators to treat metabolic disorders, cancer, and neurodegenerative disease.

Watson Pharmaceuticals, Inc. was founded in 1983 and is based in Corona, California. Watson Pharmaceuticals, Inc. (Watson) is a specialty pharmaceutical company engaged in the development, manufacture, marketing, sale and distribution of brand and generic (off-patent) pharmaceutical products. Watson operates and manages its business as three operating segments: Generic, Brand and Distribution. As of December 31, 2008, the Company marketed approximately 150 generic pharmaceutical product families and 27 brand pharmaceutical product families through its generic and brand divisions, respectively, and distributed approximately 8,000 stock-keeping units (SKUs) through its distribution division. The Company’s operations are based predominantly in the United States and India, with its key commercial market being the United States. In December 2009, the Company completed the acquisition of Arrow Group. In January 2010, the Company completed the acquisition of Eden Biopharm Group Limited.

AVI BioPharma, Inc. was founded in 1980 and is based in Corvallis, Oregon. AVI BioPharma, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products based on antisense and cancer immunotherapy technology. The company's products under various development stages comprise AVI-4658, a Phase I human clinical trial product to restore, prevent, or slow deterioration of muscle function; AVI-5038, a preclinical stage product to skip exon 50 and restore a range of associated mutations; AVI-5126, a Phase II clinical trial product for the treatment of cardiovascular restenosis; and AVI-6002 and AVI6003, which are in Phase I clinical trials to treat diseases caused by Dengue, Ebola, Marburg, and Junín viruses. It has strategic alliances with Chiron Corporation; Cook Group Incorporated; Ercole Biotech, Inc.; Eleos Inc.; Charley's Fund, Inc.; and the United States Department of Defense.

Sandoz International GmbH engages in the development, production, marketing, and distribution of generic medicines, pharmaceutical and biotechnological active substances, and anti-infectives in Germany and internationally. It offers products for various therapeutic areas, including cardiovascular system, central nervous system, gastrointestinal system, muscle and skeletal system, hormone therapy, and respiratory system. The company’s product portfolio ranges from various application forms, such as oral solids through technologies, including inhalers or injectables to transdermal patches, implants, and biopharmaceutical follow-ons. It sells its products to wholesalers, pharmacies, hospitals, and other healthcare outlets. Sandoz International GmbH was founded in 1886 and is headquartered in Holzkirchen, Germany. The company has research and development, and production sites in Boucherville, Canada; Buenos Aires, Argentina; Cambe and Taboao da Serra, Brazil; Holzkirchen/Rudolstadt and Barleben, Germany; Kolshet, Kalwe, and Mahad, India; Kundl and Schaftenau, Austria; Menges and Ljubljana, Slovenia; Wilson, North Carolina; Broomfield, Colorado; Gebze and Syntex, Turkey; and Strykow, Poland. Sandoz International GmbH operates as a subsidiary of Novartis AG.

Enzon Pharmaceuticals, Inc. company was founded in 1981 and is based in Bridgewater, New Jersey. Enzon Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing, manufacturing, and commercializing medicines for patients with cancer and other life-threatening conditions in the United States and internationally. Its products include Oncaspar, a PEG-enhanced version of a naturally occurring enzyme called L-asparaginase and is used in conjunction with other chemotherapeutics to treat patients with acute lymphoblastic leukemia; and DepoCyt, an injectable chemotherapeutic agent for the treatment of patients with lymphomatous meningitis. The company also offers Abelcet, a lipid formulation of amphotericin B used to treat immuno-compromised patients with invasive fungal infections; and Adagen, a PEGylated bovine adenosine deaminase enzyme (ADA) used to treat patients afflicted with a type of severe combined immunodeficiency disease, which is caused by the chronic deficiency of ADA. In addition, it licenses its PEGylation platform for products, such as PEG-INTRON, Pegasys, Macugen, and CIMZIA; and provides contract manufacturing services for various injectable products.Enzon is also developing PEG-SN38 for the treatment of colorectal, breast, and pancreatic cancer, as well as for non-Hodgkin's lymphoma; and HIF-1 alpha antagonist for the treatment of cancers and common solid tumors. Further, it offers Recombinant Human Mannose-Binding Lectin, a protein therapeutic to prevent and treat severe infections in individuals with low levels of MBL; and provides contract manufacturing services for various injectable products. The company has development and commercialization agreements with Santaris Pharma A/S; Schering-Plough; Sanofi-Aventis; Medac; Micromet; NatImmune A/S; Nektar; Pacira; and Cephalon France SAS. It markets its therapeutic products through its sales force that includes specialists in oncology, hematology, infectious disease, and various critical care disciplines.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.